Johnson & Johnson (NYSE: JNJ) has shared results from a midstage clinical trial of nipocalimab, highlighting mouth dryness as the top symptom Sjögren’s disease patients want to alleviate. The findings come as investors scrutinize the company’s dividend sustainability and stock valuation. JNJ’s dividend yield stands at 1.92% with a payout ratio of 57%, supported by a 3-year dividend growth rate of 4.9%. However, the stock is currently 41.8% overvalued relative to its GF Value™ of $194.73.
The DAHLIAS trial evaluated nipocalimab’s efficacy in treating Sjögren’s disease, an autoimmune disorder causing dry mouth and eyes. Interviews with 49 participants revealed that 96% prioritized mouth dryness relief, followed by fatigue (92%), eye dryness (90%), and joint pain (73%). Earlier results showed that 33% of patients on a higher nipocalimab dose saw increased saliva production, compared to 16% on placebo. The drug has received FDA breakthrough therapy and fast track designations.
Johnson & Johnson, with a market capitalization of $664.95 billion, operates in healthcare, focusing on pharmaceuticals, medical devices, and consumer health products. Its GF Score™ of 79/100 reflects strong financial health and growth prospects, though valuation and momentum are weaker. Insider activity shows net selling over the past 12 months, with $150.7 million in shares sold versus $0.3 million purchased. Meanwhile, 25 premium gurus hold JNJ shares, with mixed recent adjustments.
For income-focused investors, JNJ offers an attractive and sustainable dividend profile. However, the stock’s current valuation suggests it is significantly overvalued, which could limit near-term price appreciation. The mixed signals from insider selling and guru portfolio adjustments highlight the need to balance dividend income against valuation risks.